Want to see HK:6833 full AI Analyst Report?
6833 Stock Chart & Stats
HK$0.18
HK$0.02(7.44%)
At close: 4:00 PM EST
HK$0.18
HK$0.02(7.44%)
Day’s Range― - ―
52-Week RangeHK$0.15 - HK$0.26
Previous CloseN/A
Volume2.13M
Average Volume (3M)210.00K
Market Cap
HK$347.62M
Enterprise ValueHK$430.18
Total Cash (Recent Filing)HK$374.53M
Total Debt (Recent Filing)HK$183.47M
Price to Earnings (P/E)8.6
Beta0.32
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.98%
Share Statistics
EPS (TTM)0.02
Shares Outstanding2,032,890,600
10 Day Avg. Volume85,200
30 Day Avg. Volume210,000
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)0.47
Price to Sales (P/S)0.16
P/FCF Ratio2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Leverage And Balance-sheet ResilienceA falling debt-to-equity ratio and growing equity reduce solvency and financing risk, giving the company more flexibility to fund operations, pursue strategic initiatives or withstand shocks. This stronger balance-sheet posture supports durable operational stability over the next several months.
Rebound To Positive Operating And Free Cash FlowFresh positive operating and free cash flow indicates improved cash conversion and liquidity, enabling debt paydown, working-capital normalization or reinvestment. While past swings exist, current cash generation materially improves near-term financial flexibility and execution capacity.
Sustained Positive, If Compressed, ProfitabilityDespite margin compression from earlier years, the company remains consistently profitable at multiple income-statement levels. Positive margins support ongoing operations and provide a baseline to restore earnings power if revenue stabilizes or cost structure improves, a durable advantage over loss-making peers.
Bears Say
Sharp Revenue DeclineAn ~18% drop in revenue materially reduces scale, weakens pricing power and limits fixed-cost absorption. Prolonged top-line contraction undermines profit recovery and cash-flow resilience, increasing execution risk and reducing room to invest in growth over the coming months.
Material Margin Compression Versus Prior YearsSignificantly lower gross and operating margins squeeze retained earnings and diminish returns on capital. Thin net margins limit ability to self-fund capex or shareholder distributions and leave the business more exposed to input-cost or demand shocks over medium term.
Volatile Cash Generation With Prior Negative FCFHistoric swings in operating and free cash flow, including prior negative FCF, raise predictability risk for liquidity and planning. Even with the recent rebound, this volatility complicates budgeting, constrains consistent investment, and could re-emerge if revenue or working-capital trends weaken.
Sinco Pharmaceuticals Holdings Ltd. News
6833 FAQ
What was Sinco Pharmaceuticals Holdings Ltd.’s price range in the past 12 months?
Sinco Pharmaceuticals Holdings Ltd. lowest stock price was HK$0.15 and its highest was HK$0.26 in the past 12 months.
What is Sinco Pharmaceuticals Holdings Ltd.’s market cap?
Sinco Pharmaceuticals Holdings Ltd.’s market cap is HK$347.62M.
When is Sinco Pharmaceuticals Holdings Ltd.’s upcoming earnings report date?
Sinco Pharmaceuticals Holdings Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 18 days.
How were Sinco Pharmaceuticals Holdings Ltd.’s earnings last quarter?
Sinco Pharmaceuticals Holdings Ltd. released its earnings results on Mar 26, 2026. The company reported HK$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Sinco Pharmaceuticals Holdings Ltd. overvalued?
According to Wall Street analysts Sinco Pharmaceuticals Holdings Ltd.’s price is currently Overvalued.
Does Sinco Pharmaceuticals Holdings Ltd. pay dividends?
Sinco Pharmaceuticals Holdings Ltd. pays a Annually dividend of HK$0.002 which represents an annual dividend yield of 0.98%. See more information on Sinco Pharmaceuticals Holdings Ltd. dividends here
What is Sinco Pharmaceuticals Holdings Ltd.’s EPS estimate?
Sinco Pharmaceuticals Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sinco Pharmaceuticals Holdings Ltd. have?
Sinco Pharmaceuticals Holdings Ltd. has 2,032,890,600 shares outstanding.
What happened to Sinco Pharmaceuticals Holdings Ltd.’s price movement after its last earnings report?
Sinco Pharmaceuticals Holdings Ltd. reported an EPS of HK$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.326%.
Which hedge fund is a major shareholder of Sinco Pharmaceuticals Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:6833
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sinco Pharmaceuticals Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.16%
12-Months-Change
Fundamentals
Return on Equity
0.98%
Trailing 12-Months
Asset Growth
-3.37%
Trailing 12-Months
Company Description
Sinco Pharmaceuticals Holdings Ltd.
Sinco Pharmaceuticals Holdings Limited operates as an investment holding entity primarily specializing in the marketing, promotion, and distribution channel management of imported pharmaceutical products and medical devices throughout China. Its product portfolio includes Octapharma, a human albumin solution specifically for premature infants; Axetine, prescribed for a range of bacterial infections such as respiratory, urinary tract, soft tissue, gynecological, obstetrical, and gonorrheal infections, and for post-surgical infection prevention; and Medocef, used to treat bacterial infections affecting the lower respiratory tract (including pneumonia), urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and conditions like sepsis. The company also supplies Esafosfina, effective in managing hypophosphatemia and chronic ailments like alcohol intoxication, malnutrition, and respiratory failure due to low phosphate levels. Additionally, it offers Taurolite, a third-generation oral cholic acid drug for gallstone diseases, and Tamifil injection, indicated for metastatic prostate cancer, true precocious puberty, and endometriosis. Beyond these core services, Sinco Pharmaceuticals also conducts sales of medicinal products, operates warehousing facilities for pharmaceuticals, provides international trade services, and offers consultation in medical and biological technology. Established in 2011, the company's headquarters are situated in Chengdu, People's Republic of China, and it operates as a subsidiary of Risun Investments Limited.
Technical Analysis
Shanghai Pharmaceuticals Holding Co
―
Sinopharm Group Co
―
Dingdang Health Technology Group Ltd.
―
Kingworld Medicines Group Ltd.
―
Charmacy Pharmaceutical Co., Ltd. Class H
―